Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Altimmune (ALT) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Altimmune (ALT) over the last 17 years, with Q3 2025 value amounting to $20.9 million.

  • Altimmune's Operating Expenses fell 1577.59% to $20.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $90.5 million, marking a year-over-year decrease of 1919.88%. This contributed to the annual value of $103.2 million for FY2024, which is 709.56% up from last year.
  • As of Q3 2025, Altimmune's Operating Expenses stood at $20.9 million, which was down 1577.59% from $22.9 million recorded in Q2 2025.
  • Altimmune's Operating Expenses' 5-year high stood at $33.7 million during Q4 2023, with a 5-year trough of $15.7 million in Q1 2021.
  • Over the past 5 years, Altimmune's median Operating Expenses value was $23.0 million (recorded in 2022), while the average stood at $23.9 million.
  • In the last 5 years, Altimmune's Operating Expenses soared by 10870.43% in 2021 and then plummeted by 2611.11% in 2024.
  • Altimmune's Operating Expenses (Quarter) stood at $27.3 million in 2021, then dropped by 15.69% to $23.0 million in 2022, then skyrocketed by 46.45% to $33.7 million in 2023, then dropped by 26.11% to $24.9 million in 2024, then fell by 16.11% to $20.9 million in 2025.
  • Its Operating Expenses was $20.9 million in Q3 2025, compared to $22.9 million in Q2 2025 and $21.8 million in Q1 2025.